Asklepios BioPharmaceutical, Inc. (AskBio) has appointed Anna Tretiakova, Ph.D., as senior vice president of Product Development. Dr. Tretiakova will lead the company’s research and translational collaborations to deliver clinical candidate vectors. She reports to Jude Samulski, Ph.D., chief scientific officer and co-founder of AskBio.     

Dr. Tretiakova is an industry veteran with more than 30 years of research and development and translational medicine experience. She spent nearly 10 years exclusively focused on AAV gene therapy at the University of Pennsylvania Gene Therapy Program, Pfizer Rare Disease Research Unit and, most recently, SwanBio Therapeutics.

“Broadening our research and development team is critical to achieving our mission to transform genetic medicine, and we are excited to add Anna’s expertise moving AAV programs into the clinic,” said Dr. Samulski. “She will lead preclinical translational research across all of our existing and future therapeutic areas to ensure we pursue the highest quality candidates for clinical development.”

Dr. Tretiakova will also serve on AskBio’s leadership team tasked with driving value across the integrated gene therapy technology platforms.